Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL)
Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication
Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab
History of hypersensitivity for bevacizumab.

NCT03211741_exc_T1
Condition
pregnant
NCT03211741_exc_T2
Observation
breastfeeding
NCT03211741_exc_T3
Person
Women
NCT03211741_exc_T4
Measurement
human chorionic gonadotropin
NCT03211741_exc_T5
Procedure
human chorionic gonadotropin laboratory test
NCT03211741_exc_T6
Value
positive
NCT03211741_exc_T7
Value
> 5mIU/mL
NCT03211741_exc_T9
Condition
Tromboembolic event
NCT03211741_exc_T10
Condition
CVA
NCT03211741_exc_T11
Condition
transient ischemic attack
NCT03211741_exc_T12
Condition
AMI
NCT03211741_exc_T13
Scope
CVA or transient ischemic attack, AMI
NCT03211741_exc_T14
Temporal
less than 3 months prior to the intravitreal injection of bevacizumab
NCT03211741_exc_T15
Procedure
intravitreal injection
NCT03211741_exc_T16
Drug
bevacizumab
NCT03211741_exc_T17
Reference_point
the intravitreal injection of bevacizumab
NCT03211741_exc_T18
Condition
hypersensitivity
NCT03211741_exc_T19
Drug
bevacizumab
NCT03211741_exc_T20
Observation
History
NCT03211741_exc_T8
Person
Women
NCT03211741_exc_T21
Condition
child bearing potential
NCT03211741_exc_T22
Qualifier
effective
NCT03211741_exc_T23
Procedure
contraception
NCT03211741_exc_T24
Scope
Women of child bearing potential
NCT03211741_exc_T25
Temporal
during the trial
NCT03211741_exc_T26
Temporal
for at least 28 days following the last dose of study medication
NCT03211741_exc_T27
Multiplier
last dose
NCT03211741_exc_T28
Drug
study medication
NCT03211741_exc_T29
Reference_point
the last dose of study medication